Biotech Values

[DewDiligence]

Data from the three phase-3 Tofacitinib trials that have not already been discussed in a peer-reviewed forum—Oral Standard, Oral Step, and Oral Scan—will be presented at the ACR conference in November. The other two phase-3 Tofcitinib trials that will be included in the NDA submission are called Oral Solo and Oral Sync.

Please see the prologue of #msg-62546621 for a scorecard of the five pivotal trials in this program.